Association between levels of C-reactive protein and leukocytes and cancer: Three repeated measurements in the Swedish AMORIS study

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 3, 2011, Pages 428-437

  Van Hemelrijck, Mieke ^a   Holmberg, Lars ^a,b   Garmo, Hans ^a,b   Hammar, Niklas ^c,d   Walldius, Göran ^d   Binda, Elisa ^a   Lambe, Mats ^b,d   Jungner, Ingmar ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SKIN CANCER; UTERINE CERVIX CANCER;

AGED; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79955764220     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1190     Document Type: Article

References (34)

1. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
2. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the Creactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216-22. (Pubitemid 46631365)
3. Boffetta P. Exploring a cancer biomarker: the example of C-reactive protein. J Natl Cancer Inst 2010;102:142-3.
4. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
5. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW. Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010;39:699-709.
6. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55. (Pubitemid 35223554)
7. Ganss R, Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 1998;58:4673-81. (Pubitemid 28480634)
8. Ippoliti G, Rinaldi M, Pellegrini C, Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol 2005;56:101-13. (Pubitemid 41278649)
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
10. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12. (Pubitemid 38057722)
11. Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med 2007;167:1837-44. (Pubitemid 47481478)
12. Sprague BL, Trentham-Dietz A, Klein BE, Klein R, Cruickshanks KJ, Lee KE, et al. Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2008;17:2714-22.
13. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33. (Pubitemid 34084825)
14. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998;44:1641-9.
15. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008;264:30-8. (Pubitemid 351813479)
16. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009;265:275-87.
17. Walldius G, Jungner I, Kolar W, Holme I, Steiner E. High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction. First report from the AMORIS (Apolipoprotein related MOrtality RISk) study. Blood Press Suppl 1992;4:35-42.
18. Van Hemelrijck M, Garmo H, Binda E, Hayday A, Karagiannis SN, Hammar N, et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control 2010;21:1657-67.
19. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay between triglycerides, total cholesterol, and glucose. Cancer 2010 Nov 29. [Epub ahead of print].
20. Central Bureau for Statistics. Statistics Sweden. Stockholm, Sweden: Central Bureau for Statistics; 2008. Available from:http://www.scb.se/.
21. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis 2010;213:299-305.
22. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-6.
23. World Health Organization. Manual of Basic Techniques for a Health Laboratory. 2nd ed. Geneva, Switzerland: World Health Organization; 2003.
24. Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, , et al. Cancer Incidence in Five Continents. Vol IX. Lyon, France: IARC Scientific Publications; 2007. IARC Scientific Publication No. 160.
25. Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer 2010;127:768-79.
26. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28:2719-26.
27. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 2006;42:704-7.
28. Holzmann M, Jungner I, Walldius G, Ivert I, Nordqvist T, stergren J. Apolipoproteins B and A-I, standard lipid measures and incidence of myocardial infarction in men and women, with or without chronic kidney disease. Study IV in Thesis for doctorial degree (PhD). In: Holzmann M, editor. Renal Insufficiency, Mortality and Myocardial Infarction. Stockholm, Sweden: Karolinska Institutet; 2008.
29. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44:1358-61. (Pubitemid 28283085)
30. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;92:1834-6. (Pubitemid 40826128)
31. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 2010;103:870-6.
32. Navab M, Gharavi N, Watson AD. Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care 2008;11:459-64.
33. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:S843-57.
34. Heikkilä K, Silander K, Salomaa V, Jousilahti P, Koskinen S, Pukkala E, et al. C-reactive protein-associated genetic variants and cancer risk: Findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur J Cancer 2011;47:404-12.